Novartis South Africa (Pty) Ltd operated through various divisions including the Sandoz Specialty Division (SSD). Following amendments to the Medicines and Related Substances Act in 2004 prohibiting bonus and rebate schemes, SSD developed a marketing strategy to promote the Sandoz brand by placing its logo on medical device packaging supplied by Hiline Medical (Pty) Ltd (later renamed Maphil Trading). In August-September 2004, SSD's business manager Ms Van Jaarsveld and director Mr Van der Spuy approached Hiline about a marketing arrangement. On 14 October 2004, they presented Hiline's director Mr Lambrecht with a signed marketing agreement offering R3.5 million annually for marketing services. The agreement stated marketing activities would be finalized in Addendum A by 30 November 2004. Lambrecht orally accepted the commitment, allowing him to reduce tender prices to Mediclinic by R3 million. The specific marketing activities were agreed orally at a meeting on 12 November 2004 and confirmed via email exchanges on 30 November 2004. Both parties began performing their obligations. However, in February 2005, Novartis's chairman Mr Hallam had second thoughts. On 4 March 2005, Hallam wrote to Hiline stating there was no contract and refusing to pay invoices. Hiline (now Maphil) sued for breach of contract.